申请人:Sankyo Company, Limited
公开号:US05576340A1
公开(公告)日:1996-11-19
Compounds of formula (I): ##STR1## (wherein: R.sup.0 is hydrogen, methyl or hydroxymethyl; R.sup.1 is substituted alkyl; R.sup.2 and R.sup.3 are each hydrogen, halogen, hydroxy, alkoxy, carboxy, alkoxycarbonyl, alkyl, nitro, haloalkyl, or substituted alkyl; X is oxygen or sulfur; and Ar optionally substituted phenyl or naphthyl); and pharmaceutically acceptable salts thereof have a variety of valuable pharmaceutical activities, including anti-diabetic and anti-obesity activities; in addition, they are capable of treating or preventing hyperlipemia and hyperglycemia and, by inhibiting the action of aldose reductase, they can also be effective in the treatment and prevention of complications of diabetes.
化合物的化学式(I):##STR1##(其中:R.sup.0为氢、甲基或羟甲基;R.sup.1为取代烷基;R.sup.2和R.sup.3分别为氢、卤素、羟基、烷氧基、羧基、烷氧羰基、烷基、硝基、卤代烷基或取代烷基;X为氧或硫;Ar为可选的取代苯基或萘基);以及其药学上可接受的盐具有多种有价值的药理活性,包括抗糖尿病和抗肥胖活性;此外,它们能够治疗或预防高脂血症和高血糖,并通过抑制醛糖还原酶的作用,它们还可以有效地治疗和预防糖尿病并发症。